Among these, the PFKFB3 inhibitor PFK158 has shown significant effects in anti-tumor and anti-angiogenesis applications and has entered Phase I clinical trials (ClinicalTrials.gov: NCT02044861) [7]. Here, PFKFB3 is linked to neoplasm.